{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/12207"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/12207","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Analyzing the potential use of reovirus as an oncolytic agent","abstract":"Reovirus, which belongs to the Reoviridae family, is a non-enveloped, dsRNA viruse. Known to infect a wide range of hosts including humans, this virus is generally asymptomatic, and a majority of the population expresses anti- reoviurs antibodies from exposure during childhood. Within the last 70 years, this seemingly obscure virus has gained significant attention as a possible oncolytic virus, which as a group possess a number of qualities that make them theoretically ideal as cancer therapeutics. Namely, they are both safe and well tolerated, and specifically infect and destroy malignant cells. Theorizing that reovirus type-3 dearing would selectively infect and mediate cell death in ras activated cells, researchers have attempted to exploit this non-attenuated strain as an oncolytic virus. By analyzing pre-clinical and clinical studies of reovirus, both as a monotherapy and as part of a variety of combination therapies, I show that reovirus therapy is both safe and well tolerated, but with poorly understood efficacy. Further work is required to elucidate the mechanism behind reovirus mediated oncolysis, to fully maximize its oncolytic potential.","abstract_html":"Reovirus, which belongs to the Reoviridae family, is a non-enveloped, dsRNA viruse. Known to infect a wide range of hosts including humans, this virus is generally asymptomatic, and a majority of the population expresses anti- reoviurs antibodies from exposure during childhood. Within the last 70 years, this seemingly obscure virus has gained significant attention as a possible oncolytic virus, which as a group possess a number of qualities that make them theoretically ideal as cancer therapeutics. Namely, they are both safe and well tolerated, and specifically infect and destroy malignant cells. Theorizing that reovirus type-3 dearing would selectively infect and mediate cell death in ras activated cells, researchers have attempted to exploit this non-attenuated strain as an oncolytic virus. By analyzing pre-clinical and clinical studies of reovirus, both as a monotherapy and as part of a variety of combination therapies, I show that reovirus therapy is both safe and well tolerated, but with poorly understood efficacy. Further work is required to elucidate the mechanism behind reovirus mediated oncolysis, to fully maximize its oncolytic potential.","abstract_has_math":false,"creators":["Roy, Justin B."],"institution":"Boston University","degree_name":"Master of Arts","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013","date_published":"2013","updated_at":"2026-11-18T20:28:01Z","subjects":[],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/12207","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/12207","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F12207","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Roy, Justin B."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2015-08-04T16:01:31Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2015-08-04T16:01:31Z"]},{"key":"dc:date.issued","label":"Date","values":["2013"]},{"key":"dc:date.submitted","label":"Dc Date Submitted","values":["2013"]},{"key":"dc:publisher","label":"Institution","values":["Boston University"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Arts"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/12207"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (M.A.)--Boston University"]},{"key":"dc:description.abstract","label":"Abstract","values":["Reovirus, which belongs to the Reoviridae family, is a non-enveloped, dsRNA viruse. Known to infect a wide range of hosts including humans, this virus is generally asymptomatic, and a majority of the population expresses anti- reoviurs antibodies from exposure during childhood. Within the last 70 years, this seemingly obscure virus has gained significant attention as a possible oncolytic virus, which as a group possess a number of qualities that make them theoretically ideal as cancer therapeutics. Namely, they are both safe and well tolerated, and specifically infect and destroy malignant cells. Theorizing that reovirus type-3 dearing would selectively infect and mediate cell death in ras activated cells, researchers have attempted to exploit this non-attenuated strain as an oncolytic virus. By analyzing pre-clinical and clinical studies of reovirus, both as a monotherapy and as part of a variety of combination therapies, I show that reovirus therapy is both safe and well tolerated, but with poorly understood efficacy. Further work is required to elucidate the mechanism behind reovirus mediated oncolysis, to fully maximize its oncolytic potential."]},{"key":"dc:title","label":"Title","values":["Analyzing the potential use of reovirus as an oncolytic agent"]}]}],"canonical_facts":{"dc:creator":["Roy, Justin B."],"dc:date.accessioned":["2015-08-04T16:01:31Z"],"dc:date.available":["2015-08-04T16:01:31Z"],"dc:date.issued":["2013"],"dc:date.submitted":["2013"],"dc:description":["Thesis (M.A.)--Boston University"],"dc:description.abstract":["Reovirus, which belongs to the Reoviridae family, is a non-enveloped, dsRNA viruse. Known to infect a wide range of hosts including humans, this virus is generally asymptomatic, and a majority of the population expresses anti- reoviurs antibodies from exposure during childhood. Within the last 70 years, this seemingly obscure virus has gained significant attention as a possible oncolytic virus, which as a group possess a number of qualities that make them theoretically ideal as cancer therapeutics. Namely, they are both safe and well tolerated, and specifically infect and destroy malignant cells. Theorizing that reovirus type-3 dearing would selectively infect and mediate cell death in ras activated cells, researchers have attempted to exploit this non-attenuated strain as an oncolytic virus. By analyzing pre-clinical and clinical studies of reovirus, both as a monotherapy and as part of a variety of combination therapies, I show that reovirus therapy is both safe and well tolerated, but with poorly understood efficacy. Further work is required to elucidate the mechanism behind reovirus mediated oncolysis, to fully maximize its oncolytic potential."],"dc:identifier.uri":["https://hdl.handle.net/2144/12207"],"dc:language.iso":["en_US"],"dc:publisher":["Boston University"],"dc:title":["Analyzing the potential use of reovirus as an oncolytic agent"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Arts"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:28:01Z"}